EMA Withdrawn: Zimulti (rimonabant) — sanofi-aventis

View source ↗

Summary

The EMA has withdrawn Zimulti (rimonabant) from the market, with obesity as the therapeutic area and Sanofi-Aventis as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Zimulti (rimonabant)

Snippet

Status: Withdrawn. Therapeutic area: Obesity. MAH: sanofi-aventis. Decision date: 17/07/2008